Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

30.03.2026

1 Antimicrob Agents Chemother
1 Arch Virol
2 Epidemiol Infect
2 J Gen Virol
2 J Infect
6 J Virol
1 Lancet
13 PLoS One
7 Proc Natl Acad Sci U S A
1 Vaccine
1 Virus Res



    Antimicrob Agents Chemother

  1. ZHOU J, Yan S, Zhao Y, Zhang H, et al
    A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.
    Antimicrob Agents Chemother. 2026 Mar 23:e0166825. doi: 10.1128/aac.01668.
    >> Share


    Arch Virol

  2. KIM S, Kim JW, Ayoobi A, Lee S, et al
    A plant gallotannin pentagalloyl d-glucose elicits antiviral activity against influenza A and B viruses through multi-targeting mechanisms.
    Arch Virol. 2026;171:139.
    >> Share


    Epidemiol Infect

  3. JACKSON C, Wijlaars L, Abdullahi F, Liu M, et al
    Paediatric infection hospital admissions in England before, during, and after the COVID-19 pandemic.
    Epidemiol Infect. 2026;154:e33.
    >> Share

  4. TADA A, Otake S, Kusano T, Hoshino T, et al
    Clinical features and trends of severe paediatric group A streptococcal infections in Japan in the post-COVID-19 pandemic era.
    Epidemiol Infect. 2026;154:e35.
    >> Share


    J Gen Virol

  5. CHIU HP, Yeo YY, Lai TY, Hung CT, et al
    SARS-CoV-2 Nsp15 facilitates immune evasion and viral replication by limiting multiple host innate immune pathways, including cGAS-STING.
    J Gen Virol. 2026;107.
    >> Share

  6. AMARBAYASGALAN S, Takahashi T, Sugiura Y, Shimizu K, et al
    Bovine respiratory syncytial virus utilizes the human insulin-like growth factor 1 receptor in the late stages of infection.
    J Gen Virol. 2026;107.
    >> Share


    J Infect

  7. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
    Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia.
    J Infect. 2026;92:106727.
    >> Share

  8. ZHANG H, Kang Z, Zhang Y, Yang Y, et al
    Evolutionary dynamics and global spread of macrolide-resistant Bordetella pertussis during the post-pandemic pertussis resurgence.
    J Infect. 2026 Mar 7:106718. doi: 10.1016/j.jinf.2026.106718.
    >> Share


    J Virol

  9. BUTH SA, Marin M, Zhang Y, Avinoam O, et al
    Cyclosporine A rescues the influenza virus fusion with IFITM3-expressing cells by relocating the restriction factor to intraluminal vesicles of multivesicular bodies.
    J Virol. 2026 Mar 25:e0204525. doi: 10.1128/jvi.02045.
    >> Share

  10. KURYSHKO M, Luttermann C, Bayoumi M, Mostafa A, et al
    Host-specific functional evolution of seal influenza A virus NS1 protein following avian-to-seal transmission.
    J Virol. 2026 Mar 24:e0165025. doi: 10.1128/jvi.01650.
    >> Share

  11. LI S, Liu DX
    Interaction of coronavirus E protein with BRD2 plays important regulatory roles in viral replication and induction of pro-inflammatory response.
    J Virol. 2026 Mar 3:e0220125. doi: 10.1128/jvi.02201.
    >> Share

  12. NOORUZZAMAN M, Butt SL, Rani R, Ye C, et al
    The ORF6 accessory protein contributes to SARS-CoV-2 virulence and pathogenicity in the naturally susceptible feline model of infection.
    J Virol. 2026 Feb 27:e0064425. doi: 10.1128/jvi.00644.
    >> Share

  13. LIN S, Chen X, Luo M, Cui X, et al
    DIDS modulates VDAC1 oligomerization to suppress intrinsic apoptosis and attenuates in vitro and in vivo RSV infection.
    J Virol. 2026;100:e0220025.
    >> Share

  14. YAO Q, Mahase V, Hou W, Cruz-Cosme R, et al
    Computational and experimental identification of potential neutralizing peptides derived from human ACE2 against SARS-CoV-2 infection.
    J Virol. 2026 Jan 30:e0146825. doi: 10.1128/jvi.01468.
    >> Share


    Lancet

  15. JERNIGAN DB, Rivers CM
    Learning from swine influenza, Ebola virus disease, and Legionnaires' disease in 1976.
    Lancet. 2026 Mar 19:S0140-6736(26)00460-5. doi: 10.1016/S0140-6736(26)00460.
    >> Share


    PLoS One

  16. MA X
    Optimizing online teaching effectiveness in elementary education: Exploring multifaceted pathways based fsQCA analysis.
    PLoS One. 2026;21:e0345463.
    >> Share

  17. ATAYA F, Alamro A, Alghamdi A, Fouad D, et al
    Identification of polyphenols as novel neuropilin-1 cendR pocket inhibitors to block SARS-CoV-2 entry and enhance variant resistance.
    PLoS One. 2026;21:e0345051.
    >> Share

  18. MIKI M, Shimazu Y, Obara RD, Nagamine T, et al
    Assessment of a baloxavir marboxil treatment protocol for high pathogenicity avian influenza in Okinawa Rails, an endangered species endemic to Japan.
    PLoS One. 2026;21:e0345055.
    >> Share

  19. MATTHYS A, Amelinck L, Smet A, Ysenbaert T, et al
    Internal gene segments from a mouse-adapted influenza B virus confer increased pathogenicity to mice.
    PLoS One. 2026;21:e0335324.
    >> Share

  20. WANG L, Xia Y, Goh EH, Chen M, et al
    A smoothing and bootstrap-based framework for early outbreak detection.
    PLoS One. 2026;21:e0345088.
    >> Share

  21. NUNES BP, Crochemore-Silva I, Mielke GI, Vidaletti LP, et al
    Social inequalities in the misbelief of chloroquine's protective effect against COVID-19: results from the EPICOVID-19 study in Brazil.
    PLoS One. 2026;21:e0341666.
    >> Share

  22. FREITAS NL, Oliveira RD, Santos AKDS, Cunha-Filho M, et al
    Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients.
    PLoS One. 2026;21:e0345280.
    >> Share

  23. CORONADO GD, Dickerson JF, Tsou MH, Shivaprakash N, et al
    Temporal and geographic analyses of colorectal cancer screening during and after the COVID-19 pandemic in a federally qualified health center.
    PLoS One. 2026;21:e0345248.
    >> Share

  24. SUN X, Cappelleri JC, Lupton LL, Moran MM, et al
    Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy.
    PLoS One. 2026;21:e0345639.
    >> Share

  25. CALANCIE L, Pan Y, Bassarab K, Stowers KC, et al
    Association between local food policy council coverage and longitudinal household food insufficiency during COVID-19, stratified by race, ethnicity, and income.
    PLoS One. 2026;21:e0345654.
    >> Share

  26. DAGHER M, Abboud A, Saad GE, Itani R, et al
    Predictors of employment attrition in Lebanon during multifaceted crises: The role of chronic diseases - a national cross-sectional study.
    PLoS One. 2026;21:e0328028.
    >> Share

  27. KAWABATA J, Goto K, Maeda M, Fukuda H, et al
    Comparison of post-discharge mortality and medical expenditures in COVID-19 patients according to mechanical ventilation and extracorporeal membrane oxygenation use: The LIFE study.
    PLoS One. 2026;21:e0345939.
    >> Share

  28. SIRAPHATWONGKORN A, Methiyothin T, Onuean K, Chinnasarn K, et al
    Forecasting Thailand's mobility trends using Feature Engineered XGBoost for pandemic crisis movement management.
    PLoS One. 2026;21:e0345547.
    >> Share


    Proc Natl Acad Sci U S A

  29. SMITH E, Blaabaek EH, Reimer D, Jaeger MM, et al
    Gender gaps in reading increase during unplanned and planned school closures.
    Proc Natl Acad Sci U S A. 2026;123:e2523152123.
    >> Share

  30. BATRA H, Luo S, Saunders KO, Higgins JS, et al
    Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V(H)1-2-rearranging mouse models.
    Proc Natl Acad Sci U S A. 2026;123:e2537053123.
    >> Share

  31. VRIENDS MBL, Moran E, Calvelo M, Hansen T, et al
    Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents.
    Proc Natl Acad Sci U S A. 2026;123:e2504045123.
    >> Share

  32. BALAKRISHNAN K, Chakraborty S, Chiang C, Stratton CM, et al
    Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation.
    Proc Natl Acad Sci U S A. 2026;123:e2528398123.
    >> Share

  33. KADAM RU, Juraszek J, Brandenburg B, Garg D, et al
    Small molecule-constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins.
    Proc Natl Acad Sci U S A. 2026;123:e2537533123.
    >> Share

  34. HARIT A, Mor M, Yefet R, Izhaki-Tavor LS, et al
    Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization.
    Proc Natl Acad Sci U S A. 2026;123:e2523864123.
    >> Share

  35. VENTURA PC, Dam Jeong Y, Litvinova M, Kummer AG, et al
    VIBES: A multiscale modeling approach integrating within-host and between-hosts dynamics in epidemics.
    Proc Natl Acad Sci U S A. 2026;123:e2523055123.
    >> Share


    Vaccine

  36. FRAWLEY JE, Hutchens J, Wiley K, Mahimbo A, et al
    Uptake of Commonwealth funded influenza vaccines for Australian children aged 6-months to <5 years during the COVID-19 pandemic.
    Vaccine. 2026;79:128514.
    >> Share


    Virus Res

  37. FERREIRO I, Hurtado J, Bruno A, Cristina J, et al
    On the brink of emergence: an evolutionary approach to Influenza A virus H5N1 isolated from humans.
    Virus Res. 2026 Mar 21:199717. doi: 10.1016/j.virusres.2026.199717.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016